Octreotide acetate
Sandostatin (octreotide acetate) is an injectable prescription medication manufactured by Novartis Pharmaceuticals Corporation. It acts as a somatostatin analog, administered intravenously or subcutaneously in various strengths to help regulate hormone levels. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Sandostatin (octreotide acetate) is an injectable prescription medication manufactured by Novartis Pharmaceuticals Corporation. It acts as a somatostatin analog, administered intravenously or subcutaneously in various strengths to help regulate hormone levels. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Octreotide acetate",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Octreotide acetate — ANDA 210317 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210317"
}
]
|
| identifier | ANDA210317 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-manufacturers",
"drug-safety",
"fda",
"pharmaceuticals"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Octreotide acetate |
